GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.

NCT Number	NCT06566547
Lead Sponsor	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions	Multiple Myeloma
Enrollment	116 participants
Start Date	2024-08-26
Primary Completion	2027-05-12 (estimated)
Study Completion	2027-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-27